Research programme: immuno-oncology therapeutics - Helix BioPharma

Drug Profile

Research programme: immuno-oncology therapeutics - Helix BioPharma

Alternative Names: V-DOS-47

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator Helix BioPharma
  • Developer Helix BioPharma; Helix Polska; National Research Council Canada
  • Class CAR-T cell therapies; Drug conjugates; Immunoconjugates; Ureases
  • Mechanism of Action Apoptosis modulators; Vascular endothelial growth factor receptor-2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Breast cancer; Cancer

Most Recent Events

  • 22 Dec 2016 Helix BioPharma and ProMab Biotechnologies agree sign a non-binding letter of intent to develop chimeric antigen receptor T cell therapy (CAR-T) for Haematological malignancies and Solid tumours
  • 19 Jul 2016 Early research in Cancer in Canada (unspecified route) before July 2016
  • 06 Jan 2016 V-DOS 47 licensed to Helix Polska worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top